Literature DB >> 11811381

Nitric oxide inhibition and renal alterations.

B Jover1, A Mimran.   

Abstract

Acute and chronic administrations of L-arginine analogues are associated with renal functional and structural alterations that can be prevented or reversed by pharmacological blockade of other vasoactive systems. When given acutely, L-arginine derivatives have an antinatriuretic effect that is overridden by elevation of perfusion pressure and both endothelin and angiotensin II play an important role in the systemic and renal haemodynamic alterations associated with impaired nitric oxide availability. Long-term administration of L-arginine derivatives, mainly NG-nitro-L-arginine methylester (L-NAME), resulted in hypertension, intrarenal vascular, tubular and glomerular lesions and reduction in renal function. In prevention studies, blockade of the renin-angiotensin system markedly reduced hypertension and the renal morphological alterations associated with L-NAME administration. Although improvement in renal function may be achieved when arterial pressure is fully controlled, several reports indicate that the L-NAME-induced renal structural changes were independent of blood pressure and at least partly mediated by endothelin. In intervention studies, blockers of the renin-angiotensin system decreased but did not completely normalize arterial pressure, improved renal function and normalized albuminuria. Both the renin-angiotensin and the sympathetic nervous systems contribute to the sustained phase of chronic nitric oxide synthase inhibition, the adrenergic component being prominent with time. L-NAME hypertension can also be reversed by calcium antagonists, possibly via inhibition of angiotensin II-induced vasoconstriction, and the T-type antagonist had a greater effect than the L-type antagonist in reducing pre-glomerular resistance. The rat model of hypertension induced by chronic inhibition of nitric oxide generation has provided a useful tool to study both the development and the treatment of renal lesions resembling those found in human hypertension, a disease associated with early generalized impairment of endothelial function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11811381     DOI: 10.1097/00005344-200111002-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  The effects of combined epidural and general anesthesia on the autonomic nervous system and bioavailability of nitric oxide in patients undergoing laparoscopic pelvic surgery.

Authors:  Seokyung Shin; Sun Joon Bai; Koon Ho Rha; Yun So; Young Jun Oh
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

2.  Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis.

Authors:  J Yao; Y Zhu; W Sun; N Sawada; N Hiramatsu; M Takeda; M Kitamura
Journal:  Br J Pharmacol       Date:  2007-04-16       Impact factor: 8.739

3.  Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats.

Authors:  Jose Marcos Girardi; Rogerio Estevan Farias; Ana Paula Ferreira; Nadia Rezende Barbosa Raposo
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Direct Observation of Enhanced Nitric Oxide in a Murine Model of Diabetic Nephropathy.

Authors:  Margien G S Boels; Ernst E H van Faassen; M Cristina Avramut; Johan van der Vlag; Bernard M van den Berg; Ton J Rabelink
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

5.  Interplay between enterohaemorrhagic Escherichia coli and nitric oxide during the infectious process.

Authors:  Ilham Naïli; Marion Gardette; Annie Garrivier; Julien Daniel; Mickaël Desvaux; Mariagrazia Pizza; Alain Gobert; Thierry Marchal; Estelle Loukiadis; Grégory Jubelin
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

6.  Chronic NOS Inhibition Affects Oxidative State and Antioxidant Response Differently in the Kidneys of Young Normotensive and Hypertensive Rats.

Authors:  M Majzunova; M Kvandova; A Berenyiova; P Balis; I Dovinova; S Cacanyiova
Journal:  Oxid Med Cell Longev       Date:  2019-11-22       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.